Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback